Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes., Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.2016.34.2_suppl.210.
You can read the full text:

Read

Contributors

The following have contributed to this page